source
- Boehringer Ingelheim to invest up to $1B in AI-driven solid tumor partnership with EnvisagenicsBoehringer Ingelheim announced a partnership with Envisagenics to develop precision oncology therapies that use artificial intelligence to identify cancer-specific RNA splicing alterations. The co…
- Iambic Therapeutics eyes IPO as it pushes HER2 inhibitor IAM1363 into early trialsIambic Therapeutics, a San Diego AI‑driven biotech, said it is preparing for an initial public offering after securing several large‑scale partnerships with major pharmaceutical companies. In its…